On 16 February the revised national prostate cancer guidelines were announced. The revised guidelines state “that there is solid evidence that Stockholm3 can select men with PSA above a certain level for further investigation and, at the same time, reduce the proportion of men who need to undergo magnetic camera examination”. The guidelines have been submitted for consultation and are expected to be introduced in 2022.
”We are very pleased that the improved precision that Stockholm3 provides contributes to Sweden now evaluating modern tools for early detection of prostate cancer. This is an opportunity to save up to 1,000 lives per year in Sweden alone,” said David Rosén, CEO of A3P Biomedical.
In 2018, the Ministry of Health and Social Affairs commissioned the Regional Cancer Centers to standardize and streamline prostate cancer testing in Sweden and identify complementary diagnostic tests. Revised “National prostate cancer guidelines” have now been submitted for consultation and contain recommendations from the national working group for organized prostate cancer testing (OPT) (1).
The revised guidelines state “that there is solid evidence that Stockholm3 can select men with PSA above a certain level for further investigation and, at the same time, reduce the proportion of men who need to undergo magnetic camera examination” and that “the local OPT projects are well-suited for further clinical evaluation of Stockholm3”. The revised guidelines are planned to be introduced after the consultation round, which ends in May 2022.
(1) Referral round – National prostate cancer guidelines, February 2022
For additional information, please contact:
David Rosen, CEO
Telephone: +46 10 1823325
Stockholm3 is a blood test that combines protein markers, genetic markers, clinical data, and a proprietary algorithm, to predict the risk of aggressive prostate cancer at an early stage. In clinical practice, Stockholm3 finds 100 percent more aggressive prostate cancers and reduces 50 percent of unnecessary biopsies compared to current practice with PSA (2).
Stockholm3 has been evaluated in clinical studies with more than 75,000 men. Data from the latest pivotal study, a randomized study including 12,750 men, was published in The Lancet Oncology in 2021. Multiple studies have been published in high-impact journals, including a previous study with 58,000 men, published in The Lancet Oncology in 2015 (2).
Based on robust peer-reviewed clinical data, leading Nordic healthcare providers such as Capio S:t Görans Hospital in Sweden and Stavanger University Hospital in Norway have replaced PSA with Stockholm3. Patients benefit from a more precise test (increasing sensitivity and specificity) and healthcare providers can reduce the direct costs by 17 to 28 percent (2).
About prostate cancer
Prostate cancer is the second most common male cancer, and the fifth leading cause of cancer related death in men worldwide. According to WHO, 1.4 million men were diagnosed with prostate cancer and 375,000 deaths were reported in 2020. Incidence of prostate cancer is expected to increase by 70 percent until 2040, driven by an aging population.
About A3P Biomedical
A3P Biomedical’s mission is to improve quality of life of men by radically increasing the precision in prostate cancer diagnostics. The company’s lead product is Stockholm3, a blood test for early detection of aggressive prostate cancer. Stockholm3 has been developed by scientists at Karolinska Institutet and validated in clinical studies including more than 75,000 men. A total of SEK 750 million has been invested in clinical research, product development and market validation activities of Stockholm3. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit www.a3p.com.